Arcellx falls after FDA puts cancer therapy study on hold

Arcellx

20/06/2023 11:36

** Arcellx Inc's shares  ACLX.O  fall 22.2% to $27.8 -
amongst the biggest losers across U.S. stock exchanges premarket
    ** U.S. FDA has placed clinical hold on mid-stage study of
Arcellx's experimental therapy to treat patients with type of a
blood cancer, the biotech firm said late on Monday 
    ** Co said it is working with FDA to address the clinical
hold, which was placed following the recent death of a patient  
    ** The regulator, however, has provided clearance to
continue the dosing of patients who have undergone
lymphodepletion, is a short course of chemotherapy to kill
T-cells – a part of immune system 
    ** Co said it is working with FDA to address the clinical
hold 
    ** As of last close, stock had risen ~16% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))